220 patents
Page 7 of 11
Utility
MODULATORS OF ENaC EXPRESSION
17 Jun 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
Jeffrey R. Crosby, Shuling Guo, Huynh-Hoa Bui, Andrew T. Watt, Susan M. Freier
Filed: 31 Oct 18
Utility
Modulation of Factor 11 Expression
10 Jun 21
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof.
Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
Filed: 29 Jul 20
Utility
Conjugated Antisense Compounds for Use in Therapy
10 Jun 21
Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
Filed: 28 Jul 20
Utility
Methods for Reducing C9ORF72 Expression
10 Jun 21
Provided are methods for reducing the amount or activity of C9ORF72 RNA, and in certain instances of reducing the amount of C9ORF72 protein, in an animal.
C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene
Filed: 23 Jul 20
Utility
Methods of Modulating Antisense Activity
10 Jun 21
Disclosed herein are methods for increasing antisense activity by modulating translation.
Xue-hai Liang, Stanley T. Crooke
Filed: 16 Nov 18
Utility
Modulators of EZH2 Expression
27 May 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
Filed: 11 Apr 19
Utility
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
20 May 21
The present invention provides oligomeric compounds.
Susan M. Freier, Eric E. Swayze
Filed: 30 Jun 20
Utility
Selective Antisense Compounds and Uses Thereof
20 May 21
The present invention provides oligomeric compounds.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 30 Jun 20
Utility
Compounds and Methods for Reducing Spdef Expression
13 May 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject.
Susan M. Freier, Huynh-Hoa Bui, Shuling Guo, Jeffrey R. Crosby
Filed: 12 Jan 21
Utility
Modulation of Huntingtin Expression
13 May 21
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal.
Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Filed: 12 Oct 20
Utility
Methods of Modulating Antisense Activity
6 May 21
Disclosed herein are methods for increasing antisense oligonucleotide activity in a cell by modulating autophagy of the cell.
Joseph OCHABA, JR., Mariam AGHAJAN
Filed: 4 Apr 19
Utility
Compositions and Methods
6 May 21
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 24 Jun 20
Utility
Modulators of YAP1 Expression
29 Apr 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Filed: 31 Jan 20
Utility
Modulation of Transthyretin Expression
1 Apr 21
Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal.
Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
Filed: 1 Jun 20
Utility
Compounds and Methods for Reducing Fxi Expression
25 Mar 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 6 Nov 20
Utility
COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
25 Mar 21
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE, Mark J. GRAHAM
Filed: 1 Oct 20
Utility
Modulation of Alpha Synuclein Expression
25 Mar 21
Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression.
Susan M. Freier
Filed: 17 Sep 20
Utility
Modulation of Frataxin Expression
25 Mar 21
Certain embodiments are directed to methods and compounds for increasing FXN.
Frank RIGO, Thazha P. PRAKASH, David COREY
Filed: 21 Dec 18
Utility
Modulators of PCSK9 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 20 Nov 20
Utility
Modulators of APOL1 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Susan M. FREIER
Filed: 18 Sep 20